Kazia Therapeutics Ltd (KZIA) stock
KZIANasdaqPharmaceutical PreparationsFiscal year ends June 30
$5.49+0.18 (+3.39%)
Close on Nov 18, 2026Market cap $8.89MP/E –Yield –
Kazia Therapeutics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Kazia Therapeutics's price to sales ratio was 282.0× on Nov 11, 2026, against 284.4× a year earlier. Over the last 4 years it ranged from 1.3× to 495.4×, with a median of 151.1×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 282.0× | +12.4 |
| 2025 | Dec 31, 2025 | 269.6× | +266.3 |
| 2024 | Dec 31, 2024 | 3.3× | +1.5 |
| 2022 | Aug 31, 2022 | 1.7× | −7.3 |
| 2021 | Dec 31, 2021 | 9.0× | −131.8 |
| 2019 | Aug 30, 2019 | 140.7× | +0.5 |
| 2018 | Dec 31, 2018 | 140.2× | −260.6 |
| 2017 | Aug 31, 2017 | 400.8× | – |
See a number that looks wrong?